First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Active:	No
Cancer Type:	Breast Cancer Cervical Cancer Colon/Rectal Cancer Gynecologic Cancers Lymphoma Non-Hodgkin Lymphoma Ovarian Cancer Primary Peritoneal Cancer	NCT ID:	NCT03188965
Trial Phases:	Phase I	Protocol IDs:	18594 (primary) NCI-2018-00206 2016-004484-39
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bayer Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT03188965

Summary

The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed
for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the
proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the
maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further,
the response of the cancer to the treatment will be determined.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.